# A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19

> **NCT05381519** · PHASE2 · UNKNOWN · sponsor: **Wuhan Institute of Biological Products Co., Ltd** · enrollment: 50 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** DXP604

## Key facts

- **NCT ID:** NCT05381519
- **Lead sponsor:** Wuhan Institute of Biological Products Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05
- **Primary completion:** 2022-06
- **Final completion:** 2022-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381519, "A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05381519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*